Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7 pseudogene 32 (RPL7P32) is a processed pseudogene in the human genome, closely related to the functional ribosomal protein L7 (RPL7) gene. Pseudogenes like RPL7P32 are genomic DNA sequences similar to functional genes but generally lack protein-coding potential due to mutations or truncations and are typically not transcribed into functional proteins[2][7][10][11]. RPL7P32 was cataloged in gene databases because it shares sequence similarity with RPL7, a component of the large (60S) ribosomal subunit, but does not encode a functional protein[2][10][11]. Pseudogenes, including RPL7P32, are generally not considered therapeutic targets such as receptors, enzymes, or transporters because they do not produce functional proteins and typically lack biological activity. While emerging research has shown that some pseudogenes have regulatory roles at the RNA level in certain contexts, no evidence exists for RPL7P32 having any drug interactions, biomarker relevance, or direct disease association[2][7][10][11]. Its primary scientific importance lies in genome annotation and evolutionary studies rather than molecular targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 32 (RPL7P32).